

Appl. No. : 10/665,203
Filed : September 18, 2003

REMARKS

The Applicants have cancelled Claims 1-29 and added new Claims 30-75. After entry of the amendments, Claims 30-75 are pending in the application.

Support for Claims 30-50 and 68-75, which are directed to various compositions of therapeutic agent, including rapamycin with polyethylene glycol and the uses of these compositions, may be found in the specification, for example, in paragraph 33. Support for Claims 57-62, which are directed to preventing the wet form of age-related macular degeneration in a human, may be found in the specification, for example, in paragraphs 14 and 28. Support for Claims 63-67, which are directed to inhibiting the onset of the wet form of age-related macular degeneration in a human having the dry form of age-related macular degeneration, may be found in the specification, for example, in paragraph 14. Accordingly, no new matter is being introduced by the amendments herein.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan 10, 2006

By: Paul C. Steinhardt

Paul C. Steinhardt
Registration No. 30,806
Attorney of Record
Customer No. 20,995
(619) 235-8550

2268858:sad2
010606